Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Australia’s December Trade Surplus Expands but Falls Short of Expectations 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
SK C&C has signed a deal with Microsoft Korea for cooperation in the advancement of AI cerebral hemorrhage solutions. The former is planning to register its imaging solution on Microsoft Azure for its healthcare platform.
SK C&C said it inked the memorandum of understanding (MOU) with Microsoft Korea on Thursday, Feb. 2. It has partnered with the American tech firm so it can expand into the global market for digital healthcare solutions. The IT services unit of the SK Group is also aiming to strengthen the industry ecosystem through the deal.
As per The Korea Economic Daily, under the agreement, the Medical Insight Plus Cerebral Hemorrhage imaging medical solution that was developed by SK C&C will be filed under the Microsoft Azure Healthcare neuroradiology category which is the company's cloud platform that specializes in healthcare.
Once registered, medical clinics that would like to make use of the solution can simply buy it from the Azure Marketplace. Buyers will also be able to receive follow-up services on the platform. SK C&C will also jump into the global market by working with the in-country sales organization of Microsoft company.
"Starting with Asia and Oceania, we will actively seek out various solutions for the global healthcare market as well as customized digital IT service markets in the medical field," SK C&C's Healthcare Group's head, Yoon Dong Joon, said.
Korea Biomed Review stated that SK C&C's Medical Insight+ Brain Hemorrhage is an AI-based cerebral hemorrhage imaging solution that assesses brain CT scan images. The solution can complete the analysis within seconds. Thus, doctors are immediately informed about any bleeding or abnormalities detected. The company said that the accuracy of the software is more than 98%
SK C&C further stressed that the imaging solution software has the ability to identify even the smallest bleeding that can be missed by professional neuro-head and neck radiologists.
